Cover Image

Long-term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)-α antagonists versus TNF-α antagonists alone in psoriatic patients

Methotrexate, a folic acid analog, is the conventional systemic anti-psoriatic agent most commonly chosen for combination with biologics in the treatment of psoriasis. Real-world long-term safety data of this combination versus biologic treatment alone in dermatological practice are sparse.

Saved in:
Bibliographic Details
Main Authors: Hoffmann, Jochen (Author) , Knoop, Christian (Author) , Schäkel, Knut (Author) , Enk, Alexander (Author) , Hadaschik, Eva (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: The journal of dermatology
Year: 2021, Volume: 48, Issue: 6, Pages: 835-843
ISSN:1346-8138
DOI:10.1111/1346-8138.15754
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/1346-8138.15754
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.15754
Get full text
Author Notes:Jochen H.O. Hoffmann, Christian Knoop, Kunt Schäkel, Alexander H. Enk, Eva N. Hadaschik
Description
Summary:Methotrexate, a folic acid analog, is the conventional systemic anti-psoriatic agent most commonly chosen for combination with biologics in the treatment of psoriasis. Real-world long-term safety data of this combination versus biologic treatment alone in dermatological practice are sparse.
Item Description:First published: 20 January 2021
Gesehen am 14.09.2021
Physical Description:Online Resource
ISSN:1346-8138
DOI:10.1111/1346-8138.15754

Similar Items